Drugs / 1-(4-(DIMETHYLAMINO)PIPERIDIN-1-YL)-3-HYDROXY-3-(1-METHYL-1H-IMIDAZOL-2-YL)PROPAN-1-ONE, (S)-
1-(4-(DIMETHYLAMINO)PIPERIDIN-1-YL)-3-HYDROXY-3-(1-METHYL-1H-IMIDAZOL-2-YL)PROPAN-1-ONE, (S)-
also known as
TRK-750
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03346330 | Nov 2017 → Aug 2018 | neuropathy, painful | Toray Industries, Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04282590 | Apr 2020 → Dec 2021 | chemotherapy-induced neuropathy | Toray Industries, Inc | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 1-(4-(DIMETHYLAMINO)PIPERIDIN-1-YL)-3-HYDROXY-3-(1-METHYL-1H-IMIDAZOL-2-YL)PROPAN-1-ONE, (S)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068564 ↗ |
| Known as | TRK-750 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04282590 ↗ |
| Modality | Small molecule | — CHEMBL6068564 ↗ |
| Route | Oral | “ascending oral doses of TRK-750” NCT03346330 ↗ |